Read & Download your Issue of Thursday – January 7 FNN News

CoViD-19: An early intervention therapeutic strategy to prevent developing a severe disease as an alternative approach to control the pandemic

• The global burden of CoViD-19 on the healthcare system can be significantly reduced by targeting CoViD-19 patients with or without symptoms who are self-isolating at home or in quarantine.
• If any therapeutic support can be offered to this group of patients that could attenuate the virus within the upper respiratory tract during the early stages of CoViD-19, it can give the body the time to produce enough antibodies to recover naturally from the disease before progressing into severe disease.

Source: ScienceOpen

Antithrombotic Therapy in Patients with COVID-19

• In nonhospitalized patients with COVID-19, there are currently no data to support the measurement of coagulation markers (e.g., D-dimers, prothrombin time, platelet count, fibrinogen) (AIII).
• For nonhospitalized patients with COVID-19, anticoagulants and antiplatelet therapy should not be initiated for the prevention of venous thromboembolism (VTE) or arterial thrombosis unless the patient has other indications for the therapy or is participating in a clinical trial
• Hospitalized nonpregnant adults with COVID-19 should receive prophylactic dose anticoagulation

Source: NIH

Pentoxifylline in prevention of amphotericin B-induced nephrotoxicity and electrolyte abnormalities

• Amphotericin B is an antifungal agent used to treat serious fungal infections mainly in critically ill patients.
• Despite its adverse effects including renal toxicity and electrolyte imbalances, amphotericin B remains one of the best choices for antifungal treatment.
• Information from animal studies has provided a strong scientific basis for the use of pentoxifylline as lowering nephroprotective agent.
• The present study was designed to evaluate the efficacy of pentoxifylline in preventing renal toxicity and electrolytes imbalances induced by amphotericin B.

Source: Journal of Research in Pharmacy Practice

Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus

• Direct-acting antivirals are the recommended treatment for hepatitis C-infected patients.
• Drug–drug interactions with concomitant treatments can cause lack of effectiveness and/or safety.
• The objective of this study is to characterise drug–drug interactions of direct-acting antivirals and to analyse their influence both on the effectiveness of antiviral treatment and on the overall safety of pharmacological treatment in hepatitis C-infected patients.

Source: EJHP

Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review

• The newly emerged coronavirus (SARS-CoV-2) continues to infect humans, and no effective treatment has yet been found.
• Antibody therapy is one way to control infection caused by COVID-19.
• Heavy chain antibodies (HCAbs) are single-domain antibodies derived from the Camelidae family.
• The variable part of these antibodies (Nanobodies or VHH) has interesting properties
• In this systematic review, the application of nanobodies in the treatment of COVID-19 infection and other similar infections (MERS and SARS) was reviewed.

Source: ScienceDirect

Canakinumab as treatment for COVID-19-related pneumonia: a prospective case-control study

• Canakinumab is an IL-1β antibody that neutralizes the activity of IL-1β
• This article studied the efficacy and safety of canakinumab in patients with moderate COVID-19-related pneumonia.
• The aim of this study was to evaluate the reduction in duration of hospitalization with adequate oxygen status.
• Treatment with canakinumab in patients with COVID-19-related pneumonia rapidly restored normal oxygen status, decreased the need for invasive mechanical ventilation, and was associated with earlier hospital discharge and favorable prognosis versus SoC.

Source: ScienceDirect

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2021 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacotherapy Daily News (FNN), for a publication of E-News

Read & Download FNN Issue 8 of April 2020 FNN News